6 research outputs found
Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study
Uncertainty exists regarding the necessity of continuing triple therapy
consisting of mycophenolate mofetil (MMF), cyclosporine (CsA), and
prednisone (Pred) after kidney transplantation (RTx). At 6 mo after RTx,
212 patients were randomized to stop CsA (n = 63), stop Pred (n = 76), or
continue triple drug therapy (n = 73). The MMF dose was 1000 mg twice
daily, target CsA trough levels were 150 ng/ml, and Pred dose was 0.10
mg/kg per d. Follow-up was until 24 mo after RTx. Biopsy-proven acute
rejection occurred in 14 (22%) of 63 patients after CsA withdrawal
compared with 3 (4%) of 76 in the Pred withdrawal group (P = 0.001) and 1
(1.4%) of 73 in the control group (P = 0.0001). Biopsy-proven chronic
rejection was present in one patient in the control group, in nine
patients after CsA withdrawal (P = 0.006 versus control group); and in
four patients after discontinuation of Pred (NS). Graft loss occurred in
two versus one patient after CsA or Pred withdrawal, respectively, and in
two patients in the control group (NS). Patients who successfully withdrew
CsA had a significantly lower serum creatinine during follow-up. Pred
withdrawal resulted in a reduction in mean arterial pressure, and the
total cholesterol/HDL ratio increased. In conclusion, rapid CsA withdrawal
at 6 mo after RTx results in a significantly increased incidence of
biopsy-proven acute and chronic rejection. Pred withdrawal was safe and
resulted in a reduction in mean arterial pressure. However, patient and
graft survival and renal function 2 yr after RTx were not different among
groups
Multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners. Design of The MASTERPLAN Study [ISRCTN73187232]
BACKGROUND: Patients with chronic kidney disease (CKD) are at a greatly increased risk of developing cardiovascular disease. Recently developed guidelines address multiple risk factors and life-style interventions. However, in current practice few patients reach their targets. A multifactorial approach with the aid of nurse practitioners was effective in achieving treatment goals and reducing vascular events in patients with diabetes mellitus and in patients with heart failure. We propose that this also holds for the CKD population. DESIGN: MASTERPLAN is a multicenter randomized controlled clinical trial designed to evaluate whether a multifactorial approach with the aid of nurse-practicioners reduces cardiovascular risk in patients with CKD. Approximately 800 patients with a creatinine clearance (estimated by Cockcroft-Gault) between 20 to 70 ml/min, will be included. To all patients the same set of guidelines will be applied and specific cardioprotective medication will be prescribed. In the intervention group the nurse practitioner will provide lifestyle advice and actively address treatment goals. Follow-up will be five years. Primary endpoint is the composite of myocardial infarction, stroke and cardiovascular mortality. Secondary endpoints are cardiovascular morbidity, overall mortality, decline of renal function, change in markers of vascular damage and change in quality of life. Enrollment has started in April 2004 and the study is on track with 700 patients included on October 15th, 2005. This article describes the design of the MASTERPLAN study
Nurse practitioner care improves renal outcome in patients with CKD
Treatment goals for patients with CKD are often unrealized for many reasons, but support by nurse practitioners may improve risk factor levels in these patients. Here, we analyzed renal endpoints of the Multifactorial Approach and Superior Treatment Efficacy in Renal Patients with the Aid of Nurse Practitioners (MASTERPLAN) study after extended follow-up to determine whether strict implementation of current CKD guidelines through the aid of nurse practitioners improves renal outcome. In total, 788 patients with moderate to severe CKD were randomized to receive nurse practitioner support added to physician care (intervention group) or physician care alone (control group). Median follow-up was 5.7 years. Renal outcome was a secondary endpoint of the MASTERPLAN study. We used a composite renal endpoint of death, ESRD, and 50% increase in serum creatinine. Event rates were compared with adjustment for baseline serum creatinine concentration and changes in estimated GFR were determined. During the randomized phase, there were small but significant differences between the groups in BP, proteinuria, LDL cholesterol, and use of aspirin, statins, active vitamin D, and antihypertensive medications, in favor of the intervention group. The intervention reduced the incidence of the composite renal endpoint by 20% (hazard ratio, 0.80; 95% confidence interval, 0.66 to 0.98; P=0.03). In the intervention group, the decrease in estimated GFR was 0.45 ml/min per 1.73 m2 per year less than in the control group (P=0.01). Inconclusion, additionalsupport by nurse practitioners attenuatedthe declineof kidney function and improved renal outcome in patients with CKD. Copyrigh